# EDGAR Filing Document

**Accession Number:** 0001880438
**File Stem:** 0001193125-26-064151
**Filing Date:** 2026-2
**Character Count:** 7016
**Document Hash:** 7631b15ecd061e73b1cff04e2deed979
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-064151.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001193125-26-064151

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260220

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Easom Eric
- **CENTRAL INDEX KEY:** 0001914503

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41331
- **FILM NUMBER:** 26665863

**MAIL ADDRESS:**
- **STREET 1:** 333 3RD ST
- **CITY:** MANHATTAN BEACH
- **STATE:** CA
- **ZIP:** 90266
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AN2 Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001880438
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 820606654
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1300 EL CAMINO REAL, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** (650) 331-9090

**MAIL ADDRESS:**
- **STREET 1:** 1300 EL CAMINO REAL, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Easom Eric<br><sub>(Last) (First) (Middle)</sub><br>C/O AN2 THERAPEUTICS, INC.<br>1300 EL CAMINO REAL, SUITE 100<br><sub>(Street)</sub><br>MENLO PARK, CA 94025<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>AN2 Therapeutics, Inc. [ ANTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-20 |  | A |  | 112250<sup>(1)</sup> | A | $0 | 368630<sup>(2)</sup> | D |  |
| Common Stock |  |  |  |  |  |  |  | 1065766 | I | See Footnote<sup>(3)</sup> |
| Common Stock |  |  |  |  |  |  |  | 97058 | I | See Footnote<sup>(4)</sup> |
| Common Stock |  |  |  |  |  |  |  | 97058 | I | See Footnote<sup>(5)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $1.04 | 2026-02-20 |  | A |  | 224500 |  | <sup>(6)</sup> | 2036-02-19 | Common Stock | 224500 | $0 | 224500 | D |  |

---

### Footnotes:

(1) Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

(2) Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

(3) Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.

(4) Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.

(5) Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.

(6) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

**Signature:** /s/ Lucy Day, Attorney-in-Fact for Eric Easom  
**Date:** 2026-02-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**